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Therapeutic response in chronic lymphocytic leukaemia (CLL) is variable, with deletion or 
inactivating mutation of the TP53 gene on chromosome 17p13 being strongly associated with 
chemotherapy resistance and short survival. The UK CLL206 and German/French CLL2O 
trials demonstrated the effectiveness of combining the anti-CD52 monoclonal antibody 
alemtuzumab with high-dose methylprednisolone (HDMP) or dexamethasone in high-risk 
CLL,1, 2 and these p53-independent drug combinations became the standard of care for such 
patients in many centres prior to the advent of novel agents such as ibrutinib, idelalisib and 
venetoclax.3 The CLL210 trial was developed to evaluate the potential benefit of adding the 
cereblon-targeting drug lenalidomide to the alemtuzumab/ glucocorticoid backbone. 
Lenalidomide was of interest owing to its established activity in 17p-deleted CLL coupled 
with its potential to act in synergy with the other two drugs in a p53-independent manner.4, 5  
During the course of the study, alemtuzumab became unavailable and was replaced by the 
anti-CD20 monoclonal antibody ofatumumab, which has a reported efficacy similar to that of 
alemtuzumab.6 Although the study showed that both regimens had therapeutic activity, the 
predefined co-primary endpoints for efficacy and toxicity were not met.  
 
CLL210 was designed as a single-arm phase II trial with a randomisation to lenalidomide 
maintenance vs placebo for patients who responded to the induction phase. Patients were 
eligible if they had CLL requiring therapy by iwCLL criteria and were high-risk defined by a 
previously documented 17p deletion or TP53 mutation affecting at least 20% of CLL cells, or 
a history of not responding to or relapsing within 12 months of responding to fludarabine-
containing combination therapy irrespective of TP53 status.  
 
The study treatment consisted of dexamethasone (40mg on day 1-4 of alternate weeks from 
week 1-15), lenalidomide (5mg daily during weeks 3 and 4 and then 10mg daily during 
weeks 5-24) and alemtuzumab (30mg by subcutaneous injection thrice weekly during weeks 
7-22). Supportive care included aciclovir, pneumocytistis jiroveci prophylaxis, CMV PCR 
surveillance and G-CSF support. In the amended protocol, alemtuzumab was replaced by 12 
doses of intravenous ofatumumab (300mg on day 1 of week 7, then 1000mg weekly on day 1 
of weeks 8-15, then fortnightly on day 1 of weeks 17-21). Patients who achieved a complete 
or partial response were allowed to proceed to allogeneic haemopoietic stem-cell 
transplantation (HSCT) or were randomised to stopping treatment or continuing lenalidomide 
as maintenance therapy (10mg daily until disease progression).  
    
The efficacy and toxicity of induction therapy were evaluated using co-primary endpoints 
comprising CR rate and tolerability defined as absence of treatment-related grade 5 serious 
adverse events (SAEs) and grade 3 SAEs due to infection. The criteria for considering the 
study treatment to be of potential or definite interest were set at a CR rate of more than 10% 
or 20%, respectively, and an intolerance rate of less than 50% or 30%, respectively.  
Secondary outcomes included overall response (OR) rate, progression-free survival (PFS), 
overall survival (OS) and toxicity. Minimal residual disease (MRD) was assessed centrally by 
4-colour flow cytometry with a sensitivity of 10-4. Efficacy data were assessed by an 
independent endpoint review committee using the 2008 NCI/iwCLL criteria.7 Patients 
without progressive disease (PD) were deemed evaluable for response assessment if at least 
10 weeks of study treatment had been administered. Toxicity assessment was in accordance 
with CTCAE v4.0 with the exception of haematological toxicity which was assessed using 
the 2008 NCI/iwCLL criteria.  
 
Sixty-four patients were registered from 21 UK sites between 6 February 2012 and 8 October 
2015. Sixteen patients were recruited to the original alemtuzumab protocol until 4 September 
2012, after which 48 additional patients were recruited to the revised ofatumumab protocol 
from 13 September 2013. Baseline features of registered patients are summarised in Table 1 
and were broadly as expected. Twenty-nine (45%) patients were treatment-naïve, while the 
other 35 (55%) had received between one and three lines of prior therapy. Fifty-three (83%) 
patients had a previously recorded 17p deletion including all 29 treatment-naïve patients and 
24/35 (69%) previously treated patients. Patient characteristics were generally well balanced 
between the alemtuzumab and ofatumumab cohorts. 
 
Within the alemtuzumab cohort, 9/16 patients received all of the planned induction therapy, 
whereas treatment was terminated prematurely in 7 patients who received a median of 29 
(IQR 12, 54) percent of the planned treatment. Within the ofatumumab cohort (excluding one 
untreated patient who did not start trial treatment due to acute ITP), 24/47 patients received 
all the planned induction therapy, whereas treatment was terminated prematurely in 23 
patients who received a median of 29 (IQR 10, 38) percent of the planned treatment.  
 
Among the 16 patients in the alemtuzumab cohort, the CR/CRi, PR, SD and PD rates were 
6%, 69%, 0 and 6%, respectively, while 19% were non-evaluable due to missing data and/or 
receiving less than 10 weeks of study treatment in the absence of disease progression. Among 
the 47 patients in the ofatumumab cohort, the CR/CRi, PR, SD and PD rates were 2%, 51%, 
9% and 11%, respectively, with 28% being non-evaluable. Consequently, neither regimen 
met the predefined boundary for being of interest from an efficacy perspective. Of note, the 
6% CR rate in the alemtuzumab cohort was substantially lower than the 36% CR rate 
observed in the CLL206 trial1 which employed an 8-fold higher relative glucocorticoid dose.  
 
Kaplan-Meier curves for PFS and OS are shown in Figure 1. Despite the lower-than-expected 
CR rate in the alemtuzumab cohort, the 2-year PFS rate was surprisingly good at 58% (95% 
CI: 27-91%). This compares with ~17% in the CLL206 trial, 12% in the previously treated 
cohort of CLL2O and 56% in the treatment-naïve cohort of CLL2O (two thirds of whom 
received alemtuzumab maintenance or HSCT)1, 2 and suggests that adding lenalidomide to 
alemtuzumab and dexamethasone may prolong PFS without increasing the CR rate. In 
contrast, the 2-year PFS rate in the ofatumumab cohort of CLL210 was only 30% (95% CI: 
18-49%) with a striking difference between previously treated versus treatment-naïve patients 
(9% and 52%, respectively). 2-year OS rates were higher for the alemtuzumab cohort 
compared to the ofatumumab one (79% vs 57%).  
 
Our findings revealed interesting differences between the responses induced by the 
alemtuzumab and ofatumumab regimens. In addition to being more effective in terms of OR 
rate (75% vs 53%), CR rate (6% vs 2%), 2-year PFS (58% vs 30%), 2-year OS (79% vs 
57%), the alemtuzumab regimen produced much higher rates of blood MRD negativity (37% 
vs 0) and morphological bone marrow clearance (50% vs 8% of responders). In contrast, the 
two regimens were comparably effective at clearing nodal and splenic enlargement (25% vs 
20% of patients, respectively). 
 
Twenty patients (5 from the alemtuzumab cohort and 15 from the ofatumumab cohort) were 
randomised to lenalidomide maintenance (11) versus placebo (9). The median duration of 
lenalidomide maintenance was 6 (IQR 2, 10) months. There was a non-significant trend for 
superior PFS in the lenalidomide arm compared to the control arm and HSCT group (Figure 
1). However, these results should be interpreted with caution owing to the small number of 
patients in each group and the high post-induction drop-out rate. 
 A total of 252 grade 3 adverse events were identified from SAE and non-serious AE reports, 
among which infections (83), haematological alterations (61) and metabolic disturbances (30) 
were the most common (Table 2). Grade 3 SAEs were reported in 13/16 (81%) patients in 
the alemtuzumab cohort and 28/47 (60%) patients in the ofatumumab cohort. These included 
8 treatment-related grade 5 SAEs, of which 2 were in the alemtuzumab cohort (1 infection 
and 1 neoplasm) and 6 in the ofatumumab cohort (4 infections, 1 haematoma and 1 visceral 
arterial ischaemia). The intolerance rate was 0.67 (95% CI: 0.51-0.80) for the alemtuzumab 
cohort and 0.38 (95% CI: 0.30-0.46) for the ofatumumab cohort. Consequently, neither 
regimen met the predefined boundary for being of interest from a tolerability perspective. 
 
Neither of the two regimens evaluated in CLL210 compare favourably with newer drugs such 
as ibrutinib, idelalisib and venetoclax when applied as monotherapy to a similar patient 
population. For example, ibrutinib produced a 2-year PFS rate of 85% in a retrospective 
study of 108 patients with treatment-naïve 17p-deleted CLL8 and 65% in a combined analysis 
of 230 patients with a 17p deletion who were recruited into 3 prospective clinical trials of 
relapsed/refractory CLL.9 Similarly, the 2-year PFS rate among 46 patients with a 17p 
deletion or TP53 mutation who were recruited into a prospective clinical trial of idelalisib in 
relapsed/refractory CLL was ~43%,10 while the 2-year PFS for venetoclax in the pivotal 
study of 158 patients with predominantly relapsed/refractory 17p-deleted CLL was 54%.11  
 
In summary, although the NCRI CLL210 trial showed that lenalidomide and dexamethasone 
combined with either alemtuzumab of ofatumumab is feasible and active in high-risk CLL, 
the study did not meet the pre-specified dual primary endpoints. Furthermore, interest in 
glucocorticoid/ antibody combinations has now been eclipsed by the emergence of highly 
effective and well-tolerated novel agents that target Bcl-2 or components of the B-cell 
receptor signalling pathway.  
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Tables 
 
Table 1. Pre-treatment characteristics. 
 
  
Ofatumumab  
(N=48) 
Alemtuzumab  
(N=16) 
Total  
(N=64) 
Age [median (IQR)] 66 (59, 70) 68 (57, 74) 66 (59, 70) 
Gender [n (%)]        
Female 15 (31%) 3 (19%) 18 (28%) 
Male  33 (69%) 13 (81%) 46 (72%) 
Binet stage [n (%)] 
A 
B 
C 
Unknown 
 
10 (21%) 
12 (25%) 
25 (52%) 
1 (2%) 
 
7 (44%) 
4 (25%) 
5 (31%) 
0 (0%) 
 
17 (27%) 
16 (25%) 
30 (47%) 
1 (1%) 
IGHV Status* 
Mutated 
Unmutated 
Other** 
 
13 (27%) 
29 (60%) 
6 (13%) 
 
2 (12%) 
11 (69%) 
3 (19%) 
 
15 (23%) 
40 (63%) 
9 (14%) 
WHO performance status [n (%)]       
0 25 (52%) 9 (56%) 34 (53%) 
1 17 (35%) 7 (44%) 24 (38%) 
2 6 (13%) 0 (0%) 6 (9%) 
CIRS Total Score*** [median 
(IQR)] 2 (0, 4) 2 (1, 4) 2 (1, 4) 
CIRS Severity Index [median (IQR)] 1 (0, 2) 1 (1, 2) 1 (1, 2) 
Previous Treatment [n (%)]       
No 21 (44%) 8 (50%) 29 (45%) 
Yes 27 (56%) 8 (50%) 35 (55%) 
TP53 defect**** [n (%)]       
No 8 (17%) 3 (19%) 11 (17%) 
Yes 40 (83%) 13 (81%) 53 (83%) 
* IGHV, immunoglobulin heavy-chain variable region. IGHV genes showing >98% homology 
to the germline DNA were classed as unmutated and the remainder as mutated.  
** Other – six patients had no clonal heavy-chain variable region identified and 3 patients 
had insufficient sample to assess for IGHV status 
*** CIRS score did not include points for having CLL. 
****Previously documented TP53 defects were confirmed in pre-treatment blood samples 
from 47/53 (89%) patients and consisted of 17p deletion and TP53 mutation (33 patients), 
17p deletion only (8 patients) or TP53 mutation only (6 patients). 
  
 Table 2. Summary of all grade 3 adverse events (reported as either SAEs or non-
serious AEs) occurring with a frequency of >1%. 
 
Toxicity Induction phase Post-induction phase Total 
events 
Alemtuzumab 
group (n=16) 
Ofatumumab 
group (n=47) 
Lenalidomide 
arm (n=11) 
Control arm  
(n=9) 
Not 
randomised  
(n=18) 
Lung infection 8 13 3 3 3 30 
Neutropenia 4 15  3   2 24 
Sepsis 13 1     3 17 
Infection, other 2 5 1 1 2 11 
Febrile neutropenia 1 4 1   3 9 
Neoplasms, other   2 6   1 9 
Anaemia 2 3   1 2 8 
Hyperglycaemia 3 3     1 7 
Hypophosphataemia   4 2     6 
Thrombocytopenia 2 3       5 
Upper respiratory infection   4     1 5 
Vomiting 1 3       4 
General, other 3 1       4 
Infusion related reaction   4       4 
Bronchial infection 1 1 1 1   4 
Infective enterocolitis  1 1     2 4 
Hyponatraemia 1   2   1 4 
Hypercalcaemia   4       4 
Hypokalaemia   1 2   1 4 
Maculopapular rash 1 1 1   1 4 
Thromboembolic event   4       4 
Localised oedema 1     1 1 3 
Laryngitis 2 1       3 
 
 
 
  
Figure & Legend 
 
Figure 1. Kaplan-Meier plots comparing progression-free and overall survival of the two 
regimens used and of the subsequent randomisation after induction therapy. A) Progression-
free survival of the alemtuzumab and ofatumumab cohorts from study registration; B) overall 
survival of the alemtuzumab and ofatumumab cohorts from study registration; C) 
progression-free survival of patients who were randomised to lenalidomide maintenance or 
no further treatment or received a haematopoietic stem-cell transplant; D) overall survival of 
patients who were randomised to lenalidomide maintenance or no further treatment or 
received a haematopoietic stem-cell transplant. 
 
 
 
